DIACOMIT® (stiripentol) treatment should be undertaken under the supervision of a medical doctor who is knowledgeable about Dravet Syndrome. All initiation, change or modification of antiepileptic treatment must only be made with the approval of the medical practitioner who regularly follows the patient.

You are member of the public and have questions regarding treatments, feel free to ask a doctor or click here to view our DIACOMIT® patient information page.


Adverse events should be reported to BIOCODEX, click here to declare